Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

BackgroundImmune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs re...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Luca Galli, Giuseppe Fornarini, Paolo Andrea Zucali, Melanie Claps, Silvia Chiellino, Ilaria Zampiva, Stefania Pipitone, Riccardo Ricotta, Mariella Sorarù, Veronica Mollica, Marianna Tudini, Lucia Fratino, Veronica Prati, Orazio Caffo, Francesco Atzori, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Marilena Di Napoli, Andrea Malgeri, Emanuele Naglieri, Alessio Signori, Giuseppe Luigi Banna, Pasquale Rescigno, Linda Cerbone, Lorenzo Antonuzzo, Giandomenico Roviello
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	renal cell carcinoma bone metastases immunotherapy sodium levels efficacy outcomes
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1361010/full

Similar Items

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
by: Veronica Murianni, et al.
Published: (2024-02-01)

Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of the Meet-Uro 15 study
by: Martina Catalano, et al.
Published: (2025-02-01)

Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”
by: Sara Elena Rebuzzi, et al.
Published: (2024-12-01)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
by: Marco Stellato, et al.
Published: (2021-06-01)

International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)
by: Sara Elena Rebuzzi, et al.
Published: (2024-06-01)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
by: Giandomenico Roviello, et al.
Published: (2022-08-01)

Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study
by: Lucia Fratino, et al.
Published: (2024-02-01)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
by: Martina Catalano, et al.
Published: (2022-09-01)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
by: Giuseppe Luigi Banna, et al.
Published: (2022-10-01)

The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab
by: Giulia Claire Giudice, et al.
Published: (2025-01-01)

READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
by: L. Antonuzzo, et al.
Published: (2024-09-01)

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
by: Shobana Anpalakhan, et al.
Published: (2023-11-01)

Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration
by: Giuseppe Defazio, et al.
Published: (2025-08-01)

Systemic adjuvant therapies in renal cell carcinoma
by: Sebastiano Buti, et al.
Published: (2012-10-01)

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review
by: Giulia Mazzaschi, et al.
Published: (2023-01-01)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”
by: Melissa Bersanelli, et al.
Published: (2021-07-01)

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
by: Matteo Bauckneht, et al.
Published: (2021-03-01)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
by: Matteo Perrino, et al.
Published: (2023-01-01)

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
by: Giandomenico Roviello, et al.
Published: (2025-01-01)

Expanding Treatment Options in mUC and mRCC
by: Richard Cathomas
Published: (2022-12-01)

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study
by: Giandomenico Roviello, et al.
Published: (2026-06-01)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
by: Chiara Tommasi, et al.
Published: (2023-07-01)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
by: Amishi Y. Shah, et al.
Published: (2015-03-01)

Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists
by: Andrea Antonuzzo, et al.
Published: (2025-08-01)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
by: Melissa Bersanelli, et al.
Published: (2022-05-01)

The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer
by: Ciro Franzese, et al.
Published: (2018-09-01)

Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives
by: Irene Valle, et al.
Published: (2025-09-01)

Unconventional strategy could be the future: From target to KRAS broad range treatment
by: Sara Fancelli, et al.
Published: (2024-05-01)

Vismodegib for the treatment of radiation-induced basal cell carcinoma – a case report and brief literature study
by: Concetta Laliscia, et al.
Published: (2019-12-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Percutaneous Ablation of T1 Renal Masses: Comparative Local Control and Complications after Radiofrequency and Cryoablation
by: Lorenzo Bertolotti, et al.
Published: (2023-09-01)

Underground Nuclear Astrophysics: pushing direct measurements toward the Gamow window
by: Prati Paolo
Published: (2020-01-01)

Photodynamic therapy: development of methods and clinical applications in FCI MRCC MOH
by: M. A. Kaplan, et al.
Published: (2014-03-01)

Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
by: Eun-mi Yu, et al.
Published: (2023-04-01)

Photodynamic therapy: development of methods and clinical applications in FCI MRCC MOH
by: M. A. Kaplan, et al.
Published: (2014-01-01)

Semantic Image Synthesis via Class-Adaptive Cross-Attention
by: Tomaso Fontanini, et al.
Published: (2025-01-01)

KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients
by: Daniele Lavacchi, et al.
Published: (2023-12-01)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
by: Paolo Tralongo, et al.
Published: (2023-09-01)

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
by: Giulia Mazzaschi, et al.
Published: (2023-07-01)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
by: Daniele Lavacchi, et al.
Published: (2022-11-01)